GAITHERSBURG, Md., May 03, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be participating in two upcoming industry conferences.
Altimmune will present at the the 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference in Long Beach, CA on Wednesday, May 11, 2016 at 8:30 AM PT. The TIDES Conference provides access to an extensive network of industry leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. Bertrand Georges, Ph.D., Chief Technology Officer, will discuss Altimmune’s novel peptide vaccine platform, Densigen, and its potential to induce T cell immune responses against infectious diseases and cancer during the Peptide Vaccines and Peptide Immunotherapy session.
Bill Enright, Chief Executive Officer, is scheduled to present at the Tech Council of Maryland’s Annual Bio + Tech Conference in Bethesda, MD on Tuesday, May 24, 2016 at 10:15 AM ET in a session entitled “An Answer to the Moonshot – Immunotherapeutics.” The Maryland Bio + Tech Conference provides a forum to exchange ideas and explore partnerships that nurture the innovation economy for technology and life sciences in the Mid-Atlantic region.
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.
The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.